These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27692135)

  • 1. Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?
    Richardson A; Tolley E; Hartmann J; Reedus J; Bowlin B; Finch C; Sands CW; Self T
    Respir Med; 2016 Oct; 119():135-140. PubMed ID: 27692135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy following hospitalization for heart failure with reduced ejection fraction and association with discharge to long-term care: a cross-sectional analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population.
    Levitan EB; Van Dyke MK; Chen L; Durant RW; Brown TM; Rhodes JD; Olubowale O; Adegbala OM; Kilgore ML; Blackburn J; Albright KC; Safford MM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):249. PubMed ID: 28915854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination antihypertensive therapy among patients with COPD.
    Herrin MA; Feemster LC; Crothers K; Uman JE; Bryson CL; Au DH
    Chest; 2013 May; 143(5):1312-1320. PubMed ID: 23287970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure.
    Greene SJ; Ayodele I; Pierce JB; Khan MS; Lewsey SC; Yancy CW; Alhanti B; Van Spall HGC; Allen LA; Fonarow GC
    JACC Heart Fail; 2024 Aug; 12(8):1365-1377. PubMed ID: 38597866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.
    Kruik-Kollöffel WJ; van der Palen J; Doggen CJM; van Maaren MC; Kruik HJ; Heintjes EM; Movig KLL; Linssen GCM
    PLoS One; 2020; 15(12):e0244231. PubMed ID: 33351823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to Treatment Guidelines in Ambulatory Heart Failure Patients with Reduced Ejection Fraction in a Latin-American Country: Observational Study of the Colombian Heart Failure Registry (RECOLFACA).
    Rivera-Toquica A; Echeverría LE; Arias-Barrera CA; Mendoza-Beltrán F; Hoyos-Ballesteros DH; Plata-Mosquera CA; Ortega-Madariaga JC; Carvajal-Estupiñán JF; Quintero-Yepes V; Zárate-Correa LC; García-Peña ÁA; Velásquez-López N; Anchique CV; Saldarriaga CI; Gómez-Mesa JE
    Cardiology; 2024; 149(3):228-236. PubMed ID: 38359813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cardiologist care on 6-month outcomes in patients discharged with heart failure: results from an observational study based on administrative data.
    Avaldi VM; Lenzi J; Urbinati S; Molinazzi D; Descovich C; Campagna A; Taglioni M; Fioritti A; Fantini MP
    BMJ Open; 2017 Nov; 7(11):e018243. PubMed ID: 29101146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.
    Stefan MS; Rothberg MB; Priya A; Pekow PS; Au DH; Lindenauer PK
    Thorax; 2012 Nov; 67(11):977-84. PubMed ID: 22941975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study.
    Durstenfeld MS; Katz SD; Park H; Blecker S
    BMC Cardiovasc Disord; 2019 Aug; 19(1):194. PubMed ID: 31399059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
    Yeoh SE; Dewan P; Serenelli M; Ferreira JP; Pitt B; Swedberg K; van Veldhuisen DJ; Zannad F; Jhund PS; McMurray JJV
    Eur J Heart Fail; 2022 Mar; 24(3):529-538. PubMed ID: 34536265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pharmacist-conducted medication reconciliation at discharge on readmissions of elderly patients with COPD.
    Eisenhower C
    Ann Pharmacother; 2014 Feb; 48(2):203-8. PubMed ID: 24259651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
    Krantz MJ; Ambardekar AV; Kaltenbach L; Hernandez AF; Heidenreich PA; Fonarow GC;
    Am J Cardiol; 2011 Jun; 107(12):1818-23. PubMed ID: 21482418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-treatment mismatch in the pharmacotherapy of heart failure.
    Lee DS; Tu JV; Juurlink DN; Alter DA; Ko DT; Austin PC; Chong A; Stukel TA; Levy D; Laupacis A
    JAMA; 2005 Sep; 294(10):1240-7. PubMed ID: 16160132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.
    Hernandez AF; Mi X; Hammill BG; Hammill SC; Heidenreich PA; Masoudi FA; Qualls LG; Peterson ED; Fonarow GC; Curtis LH
    JAMA; 2012 Nov; 308(20):2097-107. PubMed ID: 23188026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Hospital Readmissions after an Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the Nationwide Readmissions Database.
    Jacobs DM; Noyes K; Zhao J; Gibson W; Murphy TF; Sethi S; Ochs-Balcom HM
    Ann Am Thorac Soc; 2018 Jul; 15(7):837-845. PubMed ID: 29611719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.
    Le Jemtel TH; Padeletti M; Jelic S
    J Am Coll Cardiol; 2007 Jan; 49(2):171-80. PubMed ID: 17222727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.